A Randomized Phase II Study of Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Latest Information Update: 18 Feb 2022
At a glance
- Drugs Toripalimab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 18 Feb 2022 New trial record